Roles of vascular and metabolic components in cognitive dysfunction of Alzheimer disease: Short- and long-term modification by non-genetic risk factors

Frontiers in Aging Neuroscience

Volumn 5, Issue NOV, 2013, Pages

  Sato, Naoyuki ^a   Morishita, Ryuichi ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Abeta; Alzhimer's disease; Diabetes mellitus; Dyslipidemia; Hypertension; Tauopathies

Indexed keywords

AMYLOID BETA PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; TAU PROTEIN;

ALZHEIMER DISEASE; BLOOD VESSEL REACTIVITY; COGNITIVE DEFECT; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFECT; DYSLIPIDEMIA; HISTOPATHOLOGY; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPOGLYCEMIA; METABOLIC DISORDER; NEUROPATHOLOGY; NONHUMAN; PHENOTYPE; PROTEIN PHOSPHORYLATION; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; VASCULAR DISEASE; VASCULAR LESION;

EID: 84895799382     PISSN: None     EISSN: 16634365     Source Type: Journal    
DOI: 10.3389/fnagi.2013.00064     Document Type: Review

References (124)

1. Araujo, D. M., Lapchak, P. A., Collier, B., Chabot, J. G., and Quirion, R. (1989). Insulin-like growth factor-1 (somatomedin-C) receptors in the rat brain: distribution and interaction with the hippocampal cholinergic system. Brain Res. 484, 130-138. doi: 10.1016/0006-8993(89)90355-7.
2. Banks, W. A. (2004). The source of cerebral insulin. Eur. J. Pharmacol. 490, 5-12. doi: 10.1016/j.ejphar.2004.02.040.
3. Basta, G., Lazzerini, G., Massaro, M., Simoncini, T., Tanganelli, P., Fu, C., et al. (2002). Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation 105, 816-822. doi: 10.1161/hc0702.104183.
4. Brownlee, M., Cerami, A., and Vlassara, H. (1988). Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318, 1315-1321. doi: 10.1056/NEJM198805193182007.
5. Bucht, G., Adolfsson, R., Lithner, F., and Winblad, B. (1983). Changes in blood glucose and insulin secretion in patients with senile dementia of Alzheimer type. Acta Med. Scand. 213, 387-392. doi: 10.1111/j.0954-6820.1983.tb03756.x.
6. Burns, M. P., Igbavboa, U., Wang, L., Wood, W. G., and Duff, K. (2006). Cholesterol distribution, not total levels, correlate with altered amyloid precursor protein processing in statin-treated mice. Neuromol. Med. 8, 319-328. doi: 10.1385/NMM:8:3:319.
7. Caballero, A. E., Arora, S., Saouaf, R., Lim, S. C., Smakowski, P., Park, J. Y, et al. (1999). Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes 48, 1856-1862. doi: 10.2337/diabetes.48.9.1856.
8. Carro, E., Trejo, J. L., Spuch, C., Bohl, D., Heard, J. M., and Torres-Aleman, I. (2006). Blockade of the insulin-like growth factor I receptor in the choroid plexus originates Alzheimer's-like neuropathology in rodents: new cues into the human disease? Neurobiol. Aging 27, 1618-1631. doi: 10.1016/j.neurobiolaging.2005.09.039.
9. Chen, D. Y., Stern, S. A., Garcia-Osta, A., Saunier-Rebori, B., Pollonini, G., Bambah-Mukku, D., et al. (2011). A critical role for IGF-II in memory consolidation and enhancement. Nature 469, 491-497. doi: 10.1038/nature09667.
10. Cohen, E., Paulsson, J. F., Blinder, P., Burstyn-Cohen, T., Du, D., Estepa, G., et al. (2009). Reduced IGF-1 signaling delays age-associated proteotoxicity in mice. Cell 139, 1157-1169. doi: 10.1016/j.cell.2009.11.014.
11. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378, 785-789. doi: 10.1038/378785a0.
12. Dartigues, J. F. (2009). Alzheimer's disease: a global challenge for the 21st century. Lancet Neurol. 8, 1082-1083. doi: 10.1016/S1474-4422(09)70298-4.
13. Demuro, G., and Obici, S. (2006). Central nervous system and control of endogenous glucose production. Curr. Diab. Rep. 6, 188-193. doi: 10.1007/s11892-006-0033-8.
14. De Strooper, B., Iwatsubo, T., and Wolfe, M. S. (2012). Presenilins and gamma-secretase: structure, function, and role in Alzheimer Disease. Cold Spring Harb. Perspect. Med. 2, a006304. doi: 10.1101/cshperspect.a006304.
15. Dickstein, D. L., Walsh, J., Brautigam, H., Stockton, S. D. Jr., Gandy, S., and Hof, P. R. (2010). Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt. Sinai J. Med. 77, 82-102. doi: 10.1002/msj.20155.
16. Dumas, A., Dierksen, G. A., Gurol, M. E., Halpin, A., Martinez-Ramirez. S., Schwab, K., et al. (2012). Functional magnetic resonance imaging detection of vascular reactivity in cerebral amyloid angiopathy. Ann. Neurol. 72, 76-81. doi: 10.1002/ana.23566.
17. Fassbender, K., Simons, M., Bergmann, C., Stroick M., Lutjohann, D., Keller, P., et al. (2001). Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 98, 5856-5861. doi: 10.1073/pnas.081620098.
18. Feldman, H. H., Doody, R. S., Kivipelto, M., Sparks, D. L., Waters, D. D., Jones, R. W., et al. (2010). Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74, 956-964. doi: 10.1212/WNL.0b013e3181d6476a.
19. Firbank, M. J., Wiseman, R. M., Burton, E. J., Saxby, B. K., O'Brien, J. T., and Ford, G. A. (2007). Brain atrophy and white matter hyperintensity change in older adults and relationship to blood pressure. Brain atrophy, WMH change and blood pressure. J. Neurol. 254, 713-721. doi: 10.1007/s00415-006-0238-4.
20. Forette. F., Seux, M. L., Staessen, J. A., Thijs, L., Babarskiene, M. R., Babeanu, S., et al. (2002). The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med. 162, 2046-2052. doi: 10.1001/archinte.162.18.2046.
21. Fotuhi, M., Hachinski, V., and Whitehouse, P. J. (2009). Changing perspectives regarding late-life dementia. Nat. Rev. Neurol. 5, 649-658. doi: 10.1038/nrneurol.2009.175.
22. Freude, S., Hettich, M. M., Schumann, C., Stohr, O., Koch, L., Kohler, C., et al. (2009a). Neuronal IGF-1 resistance reduces Abeta accumulation and protects against premature death in a model of Alzheimer's disease. FASEB J. 23, 3315-3324. doi: 10.1096/fj.09-132043.
23. Freude, S., Schilbach, K., and Schubert, M. (2009b). The role of IGF-1 receptor and insulin receptor signaling for the pathogenesis of Alzheimer's disease: from model organisms to human disease. Curr. Alzheimer Res. 6, 213-223. doi: 10.2174/156720509788486527.
24. Gasparini, L., Gouras, G. K., Wang, R., Gross, R. S., Beal, M. F., Greengard, P., et al. (2001). Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J. Neurosci. 21, 2561-2570.
25. Glenner, G. G., and Wong, C. W. (1984). Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem. Biophys. Res. Commun. 120, 885-890. doi: 10.1016/S0006-291X(84)80190-4.
26. Greenberg, S. M., and Vonsattel, J. P. (1997). Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. Stroke 28, 1418-1422. doi: 10.1161/01.STR.28.7.1418.
27. Griffith, D. N., James, I. M., Newbury, P. A., and Woollard, M. L. (1978). Abnormal cerebrovascular regulation in hypertensive patients. Br. Med. J. 2, 740. doi: 10.1136/bmj.2.6139.740.
28. Guglielmotto, M., Aragno, M., Tamagno, E., Vercellinatto, I., Visentin, S., Medana, C., et al. (2012). AGEs/RAGE complex upregulates BACE1 via NF-kappaB pathway activation. Neurobiol. Aging 33, 196e13-196e27. doi: 10.1016/j.neurobiolaging.2010.05.026.
29. Haag, M. D., Hofman, A., Koudstaal, P. J., Stricker, B. H., and Breteler, M. M. (2009). Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J. Neurol. Neurosurg. Psychiatry 80, 13-17. doi: 10.1136/jnnp.2008.150433.
30. Haass, C., Kaether, C., Thinakaran, G., and Sisodia, S. (2012). Trafficking and proteolytic processing of APP. Cold Spring Harb. Perspect. Med. 2, a006270. doi: 10.1101/cshperspect.a006270.
31. Havrankova, J., Roth, J., and Brownstein, M. (1978). Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272, 827-829. doi: 10.1038/272827a0.
32. Hayashi, S., Sato, N., Yamamoto, A., Ikegame, Y., Nakashima, S., Ogihara, T., et al. (2009). Alzheimer disease-associated peptide, amyloid beta40, inhibits vascular regeneration with induction of endothelial autophagy. Arterioscler. Thromb. Vasc. Biol. 29, 1909-1915. doi: 10.1161/ATVBAHA.109.188516.
33. Hill, J. M., Lesniak, M. A., Pert, C. B., and Roth, J. (1986). Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience 17, 1127-1138. doi: 10.1016/0306-4522(86)90082-5.
34. Hong, M., and Lee, V. M. (1997). Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J. Biol. Chem. 272, 19547-19553. doi: 10.1074/jbc.272.31.19547.
35. Iadecola, C., Park, L., and Capone, C. (2009). Threats to the mind: aging, amyloid, and hypertension. Stroke 40, S40-S44. doi: 10.1161/STROKEAHA.108.533638.
36. Iqbal, K., Alonso, A. C., Gong, C. X., Khatoon, S., Singh, T. J., and Grundke-Iqbal, I. (1994). Mechanism of neurofibrillary degeneration in Alzheimer's disease. Mol. Neurobiol. 9, 119-123. doi: 10.1007/BF02816111.
37. Iqbal, K., Liu, F., Gong, C. X., Alonso Adel, C., and Grundke-Iqbal, I. (2009). Mechanisms of tau-induced neurodegeneration. Acta Neuropathol. 118, 53-69. doi: 10.1007/s00401-009-0486-3.
38. Janson, J., Laedtke, T., Parisi, J. E., O'Brien, P., Petersen, R. C., and Butler, P. C. (2004). Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53, 474-481. doi: 10.2337/diabetes.53.2.474.
39. Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S., and Drachman, D. A. (2000). Statins and the risk of dementia. Lancet 356, 1627-1631. doi: 10.1016/S0140-6736(00)03155-X.
40. Kalaria, R. N. (2009). Neurodegenerative disease: diabetes, microvascular pathology and Alzheimer disease. Nat. Rev. Neurol. 5, 305-306. doi: 10.1038/nrneurol.2009.72.
41. Killick, R., Scales, G., Leroy, K., Causevic, M., Hooper, C., Irvine, E. E., et al. (2009). Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem. Biophys. Res. Commun. 386, 257-262. doi: 10.1016/j.bbrc.2009.06.032.
42. King, D. S., Wilburn, A. J., Wofford, M. R., Harrell, T. K., Lindley, B. J., and Jones, D. W. (2003). Cognitive impairment associated with atorvastatin and simvastatin. Pharmacotherapy 23, 1663-1667. doi: 10.1592/phco.23.15.1663.31953.
43. Kivipelto, M., Helkala, E. L., Hanninen, T., Laakso, M. P., Hallikainen, M., Alhainen, K., et al. (2001). Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 56, 1683-1689. doi: 10.1212/WNL.56.12.1683.
44. Kopf, D., and Frolich, L. (2009). Risk of incident Alzheimer's disease in diabetic patients: a systematic review of prospective trials. J. Alzheimers Dis. 16, 677-685. doi: 10.3233/JAD-2009-1011.
45. Kurinami, H., Sato, N., Shinohara, M., Takeuchi, D., Takeda, S., Shimamura, M., et al. (2008). Prevention of amyloid beta-induced memory impairment by fluvastatin, associated with the decrease in amyloid beta accumulation and oxidative stress in amyloid beta injection mouse model. Int. J. Mol. Med. 21, 531-537.
46. Launer, L. J., Ross, G. W., Petrovitch, H., Masaki, K., Foley, D., White, L. R., et al. (2000). Midlife blood pressure and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 21, 49-55. doi: 10.1016/S0197-4580(00)00096-8.
47. Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., et al. (1995). Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269, 973-977. doi: 10.1126/science.7638622.
48. Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C. X. (2011). Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J. Pathol. 225, 54-62. doi: 10.1002/path.2912.
49. Liu, Y., Liu, F., Grundke-Iqbal, I., Iqbal, K., and Gong, C. X. (2009). Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J. Neurochem. 111, 242-249. doi: 10.1111/j.1471-4159.2009.06320.x.
50. Maeda, H., Matsumoto, M., Handa, N., Hougaku, H., Ogawa, S., Itoh, T., et al. (1994). Reactivity of cerebral blood flow to carbon dioxide in hypertensive patients: evaluation by the transcranial Doppler method. J. Hypertens. 12, 191-197. doi: 10.1097/00004872-199402000-00012.
51. Maher, P. A., and Schubert, D. R. (2009). Metabolic links between diabetes and Alzheimer's disease. Expert Rev. Neurother. 9, 617-630. doi: 10.1586/ern.09.18.
52. Matsuzaki, T., Sasaki, K., Tanizaki, Y., Hata, J., Fujimi, K., Matsui, Y., et al. (2010). Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75, 764-770. doi: 10.1212/WNL.0b013e3181eee25f.
53. Mayanagi, K., Katakam, P. V., Gaspar, T., Domoki, F., and Busija, D. W. (2008). Acute treatment with rosuvastatin protects insulin resistant (C57BL/6J ob/ob) mice against transient cerebral ischemia. J. Cereb. Blood Flow Metab. 28, 1927-1935. doi: 10.1038/jcbfm.2008.81.
54. Meneilly, G. S., and Hill, A. (1993). Alterations in glucose metabolism in patients with Alzheimer's disease. J. Am. Geriatr. Soc. 41, 710-714. doi: 10.1056/NEJM198509053131013.
55. Mielke, M. M., Zandi, P. P., Sjogren, M., Gustafson, D., Ostling, S., Steen, B., et al. (2005). High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 64, 1689-1695. doi: 10.1212/01.WNL.0000161870.78572.A5.
56. Miklossy, J., Qing, H., Radenovic, A., Kis, A., Vileno, B., Laszlo, F., et al. (2008). Beta amyloid and hyperphosphorylated tau deposits in the pancreas in type 2 diabetes. Neurobiol. Aging 31, 1503-1515. doi: 10.1016/j.neurobiolaging.2008.08.019.
57. Murakami, K., Yokoyama, S., Murata, N., Ozawa, Y., Irie, K., Shirasawa, T., et al. (2011). Insulin receptor mutation results in insulin resistance and hyperinsulinemia but does not exacerbate Alzheimer's-like phenotypes in mice. Biochem. Biophys. Res. Commun. 409, 34-39. doi: 10.1016/j.bbrc.2011.04.101.
58. Muris, D. M., Houben, A. J., Schram, M. T., and Stehouwer, C. D. (2012). Microvascular dysfunction is associated with a higher incidence of type 2 diabetes mellitus: a systematic review and meta-analysis. Arterioscler. Thromb. Vasc. Biol. 32, 3082-3094. doi: 10.1161/ATVBAHA.112.300291.
59. Neumann, K. F., Rojo, L., Navarrete, L. P., Farias, G., Reyes, P., and Maccioni, R. B. (2008). Insulin resistance and Alzheimer's disease: molecular links & clinical implications. Curr. Alzheimer Res. 5, 438-447. doi: 10.2174/156720508785908919.
60. Ni Chroinin, D., Asplund, K., Asberg, S., Callaly, E., Cuadrado-Godia, E., Diez-Tejedor, E., et al. (2013). Statin therapy and outcome after ischemic stroke: systematic review and meta-analysis of observational studies and randomized trials. Stroke 44, 448-456. doi: 10.1161/STROKEAHA.112.668277.
61. Niwa, K., Younkin, L., Ebeling, C., Turner, S. K., Westaway, D., Younkin, S., et al. (2000). Abeta 1-40-related reduction in functional hyperemia in mouse neocortex during somatosensory activation. Proc. Natl. Acad. Sci. U.S.A. 97, 9735-9740. doi: 10.1073/pnas.97.17.9735.
62. Orsi, A., Sherman, O., and Woldeselassie, Z. (2001). Simvastatin-associated memory loss. Pharmacotherapy 21, 767-769. doi: 10.1592/phco.21.7.767.34577.
63. Ostrowski, S. M., Wilkinson, B. L., Golde, T. E., and Landreth, G. (2007). Statins reduce amyloid-beta production through inhibition of protein isoprenylation. J. Biol. Chem. 282, 26832-26844. doi: 10.1074/jbc. M702640200.
64. Ott, A., Stolk, R. P., van Harskamp, F., Pols, H. A., Hofman, A., and Breteler, M. M. (1999). Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53, 1937-1942. doi: 10.1212/WNL.53.9.1937.
65. Pasquier, F., Boulogne, A., Leys, D., and Fontaine, P. (2006). Diabetes mellitus and dementia. Diabetes Metab. 32(Pt 1), 403-414. doi: 10.1016/S1262-3636(07)70298-7.
66. Peters, R., Beckett, N., Forette, F., Tuomilehto, J., Clarke, R., Ritchie, C., et al. (2008). Incident dementia and blood pressure lowering in the hypertension in the very elderly trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol. 7, 683-689. doi: 10.1016/S1474-4422(08)70143-1.
67. Petrella, R. J., Shlyakhto, E., Konradi, A. O., Berrou, J. P., Sedefdjian, A., and Pathak, A. (2012). Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. J. Clin. Hypertens. (Greenwich) 14, 78-84. doi: 10.1111/j.1751-7176.2011.00577.x.
68. Pfeifer, L. A., White, L. R., Ross, G. W., Petrovitch, H., and Launer, L. J. (2002). Cerebral amyloid angiopathy and cognitive function: the HAAS autopsy study. Neurology 58, 1629-1634. doi: 10.1212/WNL.58.11.1629.
69. Prince, M. J. (1997). The treatment of hypertension in older people and its effect on cognitive function. Biomed. Pharmacother. 51, 208-212. doi: 10.1016/S0753-3322(97)81597-1.
70. Prodi, E., and Obici, S. (2006). Minireview: the brain as a molecular target for diabetic therapy. Endocrinology 147, 2664-2669. doi: 10.1210/en.2006-0143.
71. Punthakee, Z., Miller, M. E., Launer, L. J., Williamson, J. D., Lazar, R. M., Cukierman-Yaffee, T., et al. (2012). Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trial. Diabetes Care 35, 787-793. doi: 10.2337/dc11-1855.
72. Radaideh, G. A., Choueiry, P., Ismail, A., Eid, E., Berrou, J. P., Sedefdjian, A., et al. (2011). Eprosartan-based hypertension therapy, systolic arterial blood pressure and cognitive function: analysis of middle east data from the OSCAR study. Vasc. Health Risk Manag. 7, 491-495. doi: 10.2147/VHRM.S19699.
73. Rasmussen, P., Wyss, M. T., and Lundby, C. (2011). Cerebral glucose and lactate consumption during cerebral activation by physical activity in humans. FASEB J. 25, 2865-2873. doi: 10.1096/fj.11-183822.
74. Richard, F., and Pasquier, F. (2012). Can the treatment of vascular risk factors slow cognitive decline in Alzheimer's disease patients? J. Alzheimers Dis. 32, 765-772. doi: 10.3233/JAD-2012-121012.
75. Rivera, E. J., Goldin, A., Fulmer, N., Tavares, R., Wands, J. R., and de la Monte, S. M. (2005). Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J. Alzheimers Dis. 8, 247-268.
76. Rogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., et al. (1995). Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene. Nature 376, 775-778. doi: 10.1038/376775a0.
77. Roher, A. E., Esh, C. L., Kokjohn, T. A., Castano, E. M., Van Vickle, G. D., Kalback, W. M, et al. (2009). Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. Alzheimers Dement. 5, 18-29. doi: 10.1016/j.jalz.2008.10.004.
78. Rojas-Fernandez, C. H., and Cameron, J. C. (2012). Is statin-associated cognitive impairment clinically relevant? A narrative review and clinical recommendations. Ann. Pharmacother. 46, 549-557. doi: 10.1345/aph.1Q620.
79. Rotwein, P., Burgess, S. K., Milbrandt, J. D., and Krause, J. E. (1988). Differential expression of insulin-like growth factor genes in rat central nervous system. Proc. Natl. Acad. Sci. U.S.A. 85, 265-269. doi: 10.1073/pnas.85.1.265.
80. Sato, N., and Morishita, R. (2013). Plasma abeta: a possible missing link between Alzheimer disease and diabetes. Diabetes 62, 1005-1006. doi: 10.2337/db12-1549.
81. Sato, N., Takeda. S., Uchio-Yamada, K., Ueda, H., Fujisawa, T., Rakugi, H., et al. (2011). Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Curr. Aging Sci. 4, 118-127. doi: 10.2174/1874609811104020118.
82. Sato, N., Okochi, M., Taniyama, Y., Kurinami, H., Shimamura, M., Takeuchi, D., et al. (2006). Development of new screening system for Alzheimer disease, in vitro Abeta sink assay, to identify the dissociation of soluble Abeta from fibrils. Neurobiol. Dis. 22, 487-495. doi: 10.1016/j.nbd.2005.12.010.
83. Sato, N., Okochi, M., Shinohara, M., Thinakaran, G., Takeda, S., Fukumori, A., et al. (2012a). Differential regulation of amyloid precursor protein/presenilin 1 interaction during Ab40/42 production detected using fusion constructs. PLoS ONE 7:e48551. doi: 10.1371/journal.pone.0048551.
84. Sato, N., Shinohara, M., Rakugi, H., and Morishita, R. (2012b). Dual effects of statins on Abeta metabolism: upregulation of the degradation of APP-CTF and Abeta clearance. Neurodegener. Dis. 10, 305-308. doi: 10.1159/000334534.
85. Schechter, R., Beju, D., and Miller, K. E. (2005). The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem. Biophys. Res. Commun. 334, 979-986. doi: 10.1016/j.bbrc.2005.07.001.
86. Schubert, M., Brazil, D. P., Burks, D. J., Kushner, J. A., Ye, J., Flint, C. L., et al. (2003). Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J. Neurosci. 23, 7084-7092.
87. Schubert, M., Gautam, D., Surjo, D., Ueki, K., Baudler, S., Schubert, D., et al. (2004). Role for neuronal insulin resistance in neurodegenerative diseases. Proc. Natl. Acad. Sci. U.S.A. 101, 3100-3105. doi: 10.1073/pnas.0308724101.
88. Shemer, J., Raizada, M. K., Masters, B. A., Ota, A., and LeRoith, D. (1987). Insulin-like growth factor I receptors in neuronal and glial cells. Characterization and biological effects in primary culture. J. Biol. Chem. 262, 7693-7699.
89. Shepardson, N. E., Shankar, G. M., and Selkoe, D. J. (2011a). Cholesterol level and statin use in Alzheimer disease: I. Review of epidemiological and preclinical studies. Arch. Neurol. 68, 1239-1244. doi: 10.1001/archneurol.2011.203.
90. Shepardson, N. E., Shankar, G. M., and Selkoe, D. J. (2011b). Cholesterol level and statin use in Alzheimer disease: II. Review of human trials and recommendations. Arch. Neurol. 68, 1385-1392. doi: 10.1001/archneurol.2011.242.
91. Sherin, A., Anu, J., Peeyush, K. T., Smijin, S., Anitha, M., Roshni, B. T., et al. (2012). Cholinergic and GABAergic receptor functional deficit in the hippocampus of insulin-induced hypoglycemic and streptozotocin-induced diabetic rats. Neuroscience 202: 69-76. doi: 10.1016/j.neuroscience.2011.11.058.
92. Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., et al. (1995). Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375, 754-760. doi: 10.1038/375754a0.
93. Shibata, M., and Yasuda, B. (1980). New experimental congenital diabetic mice (N.S.Y. mice). Tohoku J. Exp. Med. 130, 139-142. doi: 10.1620/tjem.130.139.
94. Shimamura, M., Sato, N., Sata, M., Kurinami, H., Takeuchi, D., Wakayama, K., et al. (2007). Delayed postischemic treatment with fluvastatin improved cognitive impairment after stroke in rats. Stroke 38, 3251-3258. doi: 10.1161/STROKEAHA.107.485045.
95. Shinohara, M., Sato, N., Kurinami, H., Takeuchi, D., Takeda, S., Shimamura, M., et al. (2010). Reduction of brain beta-amyloid (Abeta) by fluvastatin, a hydroxymethylglutaryl-CoA reductase inhibitor, through increase in degradation of amyloid precursor protein C-terminal fragments (APP-CTFs) and Abeta clearance. J. Biol. Chem. 285, 22091-22102. doi: 10.1074/jbc. M110.102277.
96. Shlyakhto, E. (2007). Observational study on cognitive function and systolic blood pressure reduction (OSCAR): preliminary analysis of 6-month data from >10,000 patients and review of the literature. Curr. Med. Res. Opin. 23(Suppl. 5), S13-S18. doi: 10.1185/030079907X260719.
97. Skoog, I., Lernfelt, B., Landahl, S., Palmertz, B., Andreasson, L. A., Nilsson, L., et al. (1996). 15-Year longitudinal study of blood pressure and dementia. Lancet 347, 1141-1145. doi: 10.1016/S0140-6736(96)90608-X.
98. Skoog, I., Lithell, H., Hansson, L., Elmfeldt, D., Hofman, A., Olofsson, B., et al. (2005). Effect of baseline cognitive function and antihypertensive treatment on cognitive and cardiovascular outcomes: study on COgnition and Prognosis in the Elderly (SCOPE). Am. J. Hypertens. 18, 1052-1059. doi: 10.1016/j.amjhyper.2005.02.013.
99. Son, S. M., Song, H., Byun, J., Park, K. S, Jang, H. C., Park, Y. J., et al. (2012). Accumulation of autophagosomes contributes to enhanced amyloidogenic APP processing under insulin-resistant conditions. Autophagy 8, 1842-1844. doi: 10.4161/auto.21861.
100. Sontag, E., Nunbhakdi-Craig, V., Lee, G., Bloom, G. S., and Mumby, M. C. (1996). Regulation of the phosphorylation state and microtubule-binding activity of Tau by protein phosphatase 2A. Neuron 17, 1201-1207. doi: 10.1016/S0896-6273(00)80250-0.
101. Sparks, D. L., Scheff, S. W., Hunsaker, J. C. III, Liu, H., Landers, T., and Gross, D. R. (1994). Induction of Alzheimer-like beta-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 126, 88-94. doi: 10.1006/exnr.1994.1044.
102. Sparks, D. L., Scheff, S. W., Liu, H., Landers, T. M., Coyne, C. M., and Hunsaker, J. C. III. (1995). Increased incidence of neurofibrillary tangles (NFT) in non-demented individuals with hypertension. J. Neurol. Sci. 131, 162-169. doi: 10.1016/0022-510X(95)00105-B.
103. Stewart, R., Xue, Q. L., Masaki, K., Petrovitch, H., Ross. G. W., White, L. R, et al. (2009). Change in blood pressure and incident dementia: a 32-year prospective study. Hypertension 54, 233-240. doi: 10.1161/HYPERTENSIONAHA.109.128744.
104. Sun, X. J., Rothenberg, P., Kahn, C. R., Backer, J. M., Araki, E., Wilden, P. A., et al. (1991). Structure of the insulin receptor substrate IRS-1 defines a unique signal transduction protein. Nature 352, 73-77. doi: 10.1038/352073a0.
105. Sutherland, C., Leighton, I. A., and Cohen, P. (1993). Inactivation of glycogen synthase kinase-3 beta by phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochem. J. 296(Pt 1), 15-19.
106. Takeda, S., Sato, N., Ogihara, T., and Morishita, R. (2008). The renin-angiotensin system, hypertension and cognitive dysfunction in Alzheimer's disease: new therapeutic potential. Front. Biosci. 13:2253-2265. doi: 10.2741/2839.
107. Takeda, S., Sato, N., Takeuchi, D., Kurinami, H., Shinohara, M., Niisato, K., et al. (2009a). Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 54, 1345-1352. doi: 10.1161/HYPERTENSIONAHA.109.138586.
108. Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D., et al. (2009b). Elevation of plasma beta-amyloid level by glucose loading in Alzheimer mouse models. Biochem. Biophys. Res. Commun. 385, 193-197. doi: 10.1016/j.bbrc.2009.05.037.
109. Takeda, S., Sato, N., Rakugi, H., and Morishita, R. (2010a). Plasma beta-amyloid as potential biomarker of Alzheimer disease: possibility of diagnostic tool for Alzheimer disease. Mol. Biosyst. 6, 1760-1766. doi: 10.1039/c003148h.
110. Takeda, S., Sato, N., Uchio-Yamada, K., Sawada, K., Kunieda, T., Takeuchi, D., et al. (2010b). Diabetes-accelerated memory dysfunction via cerebrovascular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc. Natl. Acad. Sci. U.S.A. 107, 7036-7041. doi: 10.1073/pnas.1000645107.
111. Takeda, S., Sato, N., Rakugi, H., and Morishita, R. (2011). Molecular mechanisms linking diabetes mellitus and Alzheimer disease: beta-amyloid peptide, insulin signaling, and neuronal function. Mol. Biosyst. 7, 1822-1827. doi: 10.1039/c0mb00302f.
112. Takeda, S., Sato, N., Uchio-Yamada, K., Yu, H., Moriguchi, A., Rakugi, H., et al. (2012). Oral glucose loading modulates plasma beta-amyloid level in Alzheimer's disease patients: potential diagnostic method for Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 34, 25-30. doi: 10.1159/000338704.
113. Talbot, K., Wang, H. Y., Kazi, H., Han, L. Y., Bakshi, K. P., Stucky, A., et al. (2012). Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J. Clin. Invest. 122, 1316-1338. doi: 10.1172/JCI59903.
114. Tokutake, T., Kasuga, K., Yajima, R., Sekine, Y., Tezuka, T., Nishizawa, M., et al. (2012). Hyperphosphorylation of tau induced by naturally secreted amyloid-beta at low nanomolar concentrations is modulated by insulin-dependent AKT-GSK3beta signaling pathway. J. Biol. Chem. 287, 35222-35233. doi: 10.1074/jbc. M112.348300.
115. Ueda, H., Ikegami, H., Kawaguchi, Y., Fujisawa, T., Nojima, K., Babaya, N., et al. (2000). Age-dependent changes in phenotypes and candidate gene analysis in a polygenic animal model of Type II diabetes mellitus; NSY mouse. Diabetologia 43, 932-938. doi: 10.1007/s001250051472.
116. van de Nes, J. A., Kamphorst, W., Ravid, R., and Swaab, D. F. (1998). Comparison of beta-protein/A4 deposits and Alz-50-stained cytoskeletal changes in the hypothalamus and adjoining areas of Alzheimer's disease patients: amorphic plaques and cytoskeletal changes occur independently. Acta Neuropathol. 96, 129-138. doi: 10.1007/s004010050872.
117. van Elderen, S. G., de Roos, A., de Craen, A. J., Westendorp, R. G., Blauw, G. J., Jukema, J. W., et al. (2010). Progression of brain atrophy and cognitive decline in diabetes mellitus: a 3-year follow-up. Neurology 75, 997-1002. doi: 10.1212/WNL.0b013e3181f25f06.
118. Wagstaff, L. R., Mitton, M. W., Arvik, B. M., and Doraiswamy, P. M. (2003). Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 23, 871-880. doi: 10.1592/phco.23.7.871.32720.
119. Wang, J., Ho, L., Chen, L., Zhao, Z., Zhao, W., Qian, X., et al. (2007). Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J. Clin. Invest. 117, 3393-3402. doi: 10.1172/JCI31547.
120. Whitmer, R. A., Karter, A. J., Yaffe, K., Quesenberry, C. P. Jr., and Selby, J. V. (2009). Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301, 1565-1572. doi: 10.1001/jama.2009.460.
121. Wickelgren, I. (1998). Tracking insulin to the mind. Science 280, 517-519. doi: 10.1126/science.280.5363.517.
122. Wolozin, B., Kellman, W., Ruosseau, P., Celesia, G. G., and Siegel, G. (2000). Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 57, 1439-1443. doi: 10.1001/archneur.57.10.1439.
123. Wyss, M. T., Jolivet, R., Buck, A., Magistretti, P. J., and Weber, B. (2011). In vivo evidence for lactate as a neuronal energy source. J. Neurosci. 31, 7477-7485. doi: 10.1523/JNEUROSCI.0415-11.2011.
124. Zhang, Y., Zhou, B., Deng, B., Zhang, F., Wu, J., Wang, Y., et al. (2013). Amyloid-beta induces hepatic insulin resistance in vivo via JAK2. Diabetes 62, 1159-1166. doi: 10.2337/db12-0670.